Zhao Bonan, Li Xiang, Kong Ying, Wang Wenbo, Wen Tingting, Zhang Yanru, Deng Zhiyong, Chen Yafang, Zheng Xian
Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, Netherlands.
Department of Central Laboratory and Precision Medicine Center, Department of Nephrology, The Affiliated Huai'an Hospital of Xuzhou Medical University and Huai'an Second People's Hospital, Huai'an, China.
Front Bioeng Biotechnol. 2022 Sep 8;10:1010724. doi: 10.3389/fbioe.2022.1010724. eCollection 2022.
Immunotherapy has demonstrated great clinical success in the field of oncology in comparison with conventional cancer therapy. However, cancer immunotherapy still encounters major challenges that limit its efficacy against different types of cancers and the patients show minimal immune response to the immunotherapy. To overcome these limitations, combinatorial approaches with other therapeutics have been applied in the clinic. Simultaneously, nano-drug delivery system has played an important role in increasing the antitumor efficacy of various treatments and has been increasingly utilized for synergistic immunotherapy to further enhance the immunogenicity of the tumors. Specifically, they can promote the infiltration of immune cells within the tumors and create an environment that is more sensitive to immunotherapy, particularly in solid tumors, by accelerating tumor accumulation and permeability. Herein, this progress report provides a brief overview of the development of nano-drug delivery systems, classification of combinatory cancer immunotherapy and recent progress in tumor immune synergistic therapy in the application of nano-drug delivery systems.
与传统癌症治疗相比，免疫疗法在肿瘤学领域已展现出巨大的临床成功。然而，癌症免疫疗法仍面临重大挑战，这些挑战限制了其对不同类型癌症的疗效，且患者对免疫疗法的免疫反应极小。为克服这些限制，与其他疗法的联合方法已应用于临床。同时，纳米药物递送系统在提高各种治疗的抗肿瘤疗效方面发挥了重要作用，并越来越多地用于协同免疫疗法，以进一步增强肿瘤的免疫原性。具体而言，它们可促进免疫细胞在肿瘤内的浸润，并通过加速肿瘤积累和通透性，营造一个对免疫疗法更敏感的环境，尤其是在实体瘤中。在此，本进展报告简要概述了纳米药物递送系统的发展、联合癌症免疫疗法的分类以及纳米药物递送系统在肿瘤免疫协同治疗中的最新进展。
